

Changes in Chemosensory Sensation during COVID-19

ORIGINAL CONTRIBUTION

Smell, taste and chemesthesis disorders in patients with the SARS-CoV-2 Omicron variant in China

Ying Chen^{1,†}, Yuying Chen^{1,†}, Xiang Liu², Chao Yan³, Laiquan Zou^{1,*}

¹ Chemical Senses and Mental Health Lab, Department of Psychology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China

² Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

³ Key Laboratory of Brain Functional Genomics (MOE & STCSM), Shanghai Changning-ECNU Mental Health Center, School of Psychology and Cognitive Science, East China Normal University, Shanghai, China

* Correspondence: zoulq@smu.edu.cn; Tel.: +86-20-62789234

† These authors contributed equally to this work.

Main text word count: 2336 words

SUMMARY

Background: Chemosensory disorders (including smell, taste and chemesthesis) are among the established symptoms of COVID-19 infection; however, new data indicate that the changes in chemosensory sensation caused by COVID-19 may differ among populations and COVID-19 variants. To date, few studies have focused on the influence of the SARS-CoV-2 Omicron variant on qualitative changes and quantitative reductions in chemosensory function in China.

Methodology: We conducted a cross-sectional study of patients with COVID-19 caused by the Omicron variant, to investigate the prevalence of chemosensory disorders and chemosensory function before and during infection, using an online questionnaire.

Results: A total of 1245 patients with COVID-19 completed the survey. The prevalence rates of smell, taste, and chemesthesis disorders were 69.2%, 67.7%, and 31.4%, respectively. Our data indicate that sex, age, smoking, and COVID-19-related symptoms, such as lack of appetite, dyspnea, and fatigue, may be associated with chemosensory disorders during COVID-19.

Conclusions: Self-rating of chemosensory function revealed that patients experienced a general decline in smell, taste, and chemesthesis function. Further longitudinal research studies are needed to generate additional data based on objective assessment and investigate the factors influencing chemosensory function in COVID-19.

Key words: chemosensory, COVID-19, cross-sectional studies, Omicron, prevalence

INTRODUCTION

Coronavirus disease 2019 (COVID-19) was first detected in Wuhan in December 2019, and rapidly spread throughout more than 80 countries^(1,2). Information from the World Health Organization shows that the number of confirmed COVID-19 cases was 756,411,740 by 16 February, 2023 (<https://covid19.who.int>). There are reports that chemosensory disorders are important symptoms of COVID-19 infection⁽³⁻⁵⁾. Studies from the United States, Europe, Malaysia, and Singapore demonstrated that 12%–

88% of COVID-19-infected patients have olfactory and taste disorders^(4,6–8), while studies from China reported that 5%–25% of patients have smell and/or taste disorder^(9,10). The Omicron variant of SARS-CoV-2 was first detected in South Africa in November 2021, and became the main epidemic strain in the world by 15 January 2022^(11,12). Some studies have found that the Omicron variant causes less smell and taste dysfunction than non-Omicron SARS-CoV-2^(13–15). Further, a meta-analysis found that the prevalence rates of olfactory dysfunction caused by the Omicron variant are 8%–17% and 2%–17% in the UK and USA, respectively⁽¹⁵⁾. In China, the prevalence of olfactory dysfunction caused by the Omicron variant is reported as 0–9%^(16–20); however, the sample sizes of studies to date have been relatively small and researchers have focused on patient characteristics and clinical symptoms, with insufficient discussion of chemosensory changes. Chemosensory sensation (including smell, taste, and chemesthesis) have important roles in sensing potential threats, such as toxins, bacteria, and chemical irritants⁽²¹⁾, but most relevant studies have focused solely on smell and taste, and ignored chemesthesis, which is defined as detection of burning, cooling, or tingling in the mouth^(5,21). Since these three systems are independent sensory systems, with distinct peripheral and central neural mechanisms⁽²²⁾, it is necessary to explore the influence of COVID-19 on these three senses separately. Further, chemosensory disturbances can result in qualitative changes or quantitative reductions in smell or taste, associated with different mechanisms. Qualitative changes include parosmia (things smell different from usual), phantosmia (hallucination of olfactory senses), smell fluctuation, parageusia (distorted taste sensations) and phantogeusia (hallucination of gustatory senses). Quantitative reductions include anosmia (complete loss of olfaction), hyposmia (partial loss of olfaction), ageusia (loss of all or specific gustatory senses) and hypogeusia (reduced ability to taste things)^(23,24). Previous studies have generally explored changes or reductions of smell and taste, but have rarely classified patient conditions according to the qualitative of the disorders. There is a pressing need to conduct a cross-sectional study to assess the effects of Omicron on patient smell, taste, and chemesthesis in China. The primary aim of this study was to investigate the prevalence of chemosensory disorders, as well as qualitative and quantitative changes of the chemosensory senses during Omicron infection. A secondary aim was to identify factors associated with chemosensory disorders, including sex, age, alcohol intake, chronic rhinitis, allergic rhinitis, and comorbidity or specific conditions, as well as COVID-19 related characteristics.

MATERIALS AND METHODS

Participants

Participants answered questions in an online survey about their sociodemographic characteristics, COVID-19 infection status, and smell, taste, and chemesthesis between 20 December 2022 and 20 January 2023. A total of 1311 patients (all aged ≥ 18 years) recovered from COVID-19 were invited to participate in the survey. Participants who did not answer all of the questions or failed to pass the lie test were excluded. The final sample consisted of 1245 participants: 983 women (79.0%) and 262 men (21.0%), with a mean \pm standard deviation (SD) age of 25.45 ± 6.57 years old. As this was a cross-sectional study, a 0.95 power estimate, an effect size of 0.3, and an α value of 0.05 were used to calculate the necessary sample size in the G*Power program⁽²⁵⁾. The sample size in our study was far larger than the result proposed by the G*Power program. All participants read an informed consent form and agreed to the use of their data for research. This study received ethics approval

from the Ethics Committee of Southern Medical University.

Data collection

A self-administered questionnaire was used to survey patients who had recovered from COVID-19 in China. The questionnaire was adapted from existing online questionnaires developed by the Global Consortium for Chemosensory Research (GCCR) ⁽⁵⁾. The GCCR core questionnaire has been implemented in 10 languages as of April 18, 2020, and used or adapted in many other research studies ^(4,26,27). Data collected included demographic information, COVID-19-related characteristics, and patient chemosensory situations, before and during infection. To study the sense of smell and taste in further detail, smell situation options included anosmia, hyposmia, parosmia, phantosmia, and smell fluctuation, and taste situation options included ageusia, hypogeusia, parageusia, and phantogeusia ^(5,24).

Statistical analysis

Associations between categorical variables were tested using the Chi-Square test. Self-ratings of smell, taste, and chemesthesis before and during COVID-19 diagnosis were evaluated using the Wilcoxon matched pairs signed-rank test. Statistical significance was set at $p < 0.05$ and all reported p values are two-tailed. All statistical analyses were performed using IBM SPSS Statistics (SPSS, version 22).

RESULTS

General prevalence

Of 1245 patients infected with COVID-19, 69.2% (861/1245) reported having smell disorder, 67.7% (843/1245) reported having taste disorder, and 31.4% (391/1245) reported chemesthesis disorder (Table 1); the prevalence rates of specific types of smell and taste disorder are also shown in Table 1. Among patients who experienced anosmia or hyposmia ($n = 819$), only 12.3% (101/819) reported that the anosmia or hyposmia was completely caused by nasal congestion. Further, 56.9% (708/1245) of patients reported loss of both smell and taste, 12.3% (153/1245) reported loss of smell only, and 10.8% (135/1245) reported loss of taste only.

Smell disorder

The data presented in Table 2 show that there was a statistically significant difference in smoking status between patients with and without smell disorder ($p < 0.05$); where smell disorder was significantly more common among patients who were current or former smokers ($p < 0.05$). No statistically significant differences in other demographic characteristics, including sex, age group, alcohol intake, chronic rhinitis, allergic rhinitis, and comorbidity or special condition, were found between patients with and without smell disorder (all $p > 0.05$). Significant differences in rehabilitation status, COVID-19-related symptoms (lack of appetite, dry and sore throat, myalgia, stuffy/running nose, dyspnea and fatigue), and COVID-19 vaccination status, were also observed between patients with and without smell disorder (all $p < 0.05$). Chi-square analysis indicated that patients with symptoms including lack of appetite, dry and sore throat, myalgia, stuffy/running nose, dyspnea, and fatigue, were prone to having smell disorder. Further, patients who did not undergo COVID-19 vaccination were more likely to experience smell disorder ($p < 0.05$). Associations between specific types of smell disorder (anosmia, hyposmia, parosmia, phantosmia, and olfactory fluctuation) and demographic/COVID-19-related characteristics are presented in the supplemental material (Table S1–S5).

Only 4.8% (60/1245) of patients reported parosmia, while 7.9% (98/1245) reported phantosmia. Pleasantness rating score on 100-point scale of the distorted smell caused by parosmia was 25.72 ± 24.81 (Mean \pm SD), and that of phantom smells was 26.74 ± 25.98 (Mean \pm SD). Parosmic individuals mostly reported smells of food (e.g., meat, rice, or soup) or other daily necessities (e.g., toothpaste, shampoo, or liquid detergent) that became roasted, burnt, or spoiled (e.g., “The smell of chicken soup turned to burning”). In phantomic individuals, the most frequently reported phantom smells were smoky, burnt, and rotten.

Patients rated their smell function before and during COVID-19 on a 100-point scale. Compared to scores before COVID-19 (88.53 ± 13.24 , Mean \pm SD), those during COVID-19 (52.38 ± 32.83 , Mean \pm SD) were significantly lower ($t = 38.386$, $p < 0.001$) (Figure 1).

Taste disorder

There were no statistically significant differences in demographic characteristics, such as sex, age group, and smoking/alcohol intake, between patients with and without taste disorder (all $p > 0.05$, Table 3). Patients with COVID-19-related symptoms, such as lack of appetite, dry and sore throat, myalgia, headache, diarrhea, cough/expectoration, stuffy/runny nose, dyspnea, and fatigue had a significant chance of experiencing taste disorder (all $p < 0.05$). Associations between specific types of taste disorder (ageusia, hypogeusia, parageusia, phantogeusia) and demographic/COVID-19-related characteristics are detailed in the supplemental material (Table S6–S9). Additionally, of patients with total loss or decrease of specific taste ($n = 597$), 36.9% (220/597) reported total loss or decrease in the taste of sour, 45.9% (274/597) of sweet, 20.1% (120/597) of bitter, 51.4% (307/597) of salty, and 71.9% (429/597) of umami.

Parageusia was described in 22.7% (282/1245) of patients, while phantogeusia was identified in 26.7% (333/1245) of patients. Pleasantness rating score on 100-point scale of the distorted gustatory sense caused by parosmia was 19.80 ± 21.33 (Mean \pm SD), while that for gustatory hallucination was 24.97 ± 34.38 (Mean \pm SD). Most patients with parageusia described that the flavors of foods, such as orange, meat, or candy, became bitter (e.g., “The rice has turned bitter”). Patients with phantogeusia most frequently reported a constant bitter flavor, without anything in mouth.

Similar to smell, patients rated their taste function before and during COVID-19. The score during COVID-19 (58.78 ± 29.74 , Mean \pm SD) was significantly lower than that before COVID-19 (90.13 ± 11.60 , Mean \pm SD) ($t = 37.173$, $p < 0.001$).

Chemesthesis disorder

No significant differences in demographic characteristics, including sex, age group, smoking and alcohol intake, chronic rhinitis, allergic rhinitis, and any comorbidity or special condition, were found between patients with and without chemesthesis disorder (all $p > 0.05$, Table 4). Significant differences in COVID-19-related symptoms (lack of appetite, dyspnea, and fatigue) were detected between patients with and without chemesthesis disorder (all $p < 0.05$).

Patients also rated their chemesthesis function before and during COVID-19. The score during COVID-19 (71.82 ± 26.48 , Mean \pm SD) was also significantly lower than that before COVID-19 (88.50 ± 15.83 , Mean \pm SD) ($t = 24.700$, $p < 0.001$).

DISCUSSION

In the current study, we found that the prevalence rates of smell, taste, and

chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron variant dominance were 69.2%, 67.7%, and 31.4%, respectively. Previous studies reported prevalence rates of olfactory dysfunction ranging from 3.2% to 98.3% and of taste dysfunction ranging from 5.6% to 62.7%^(28,29). Previous research has found that the reported prevalence of smell, taste, and chemesthesis disorder varies according to differences in population, assessment method, and virus strain⁽²⁸⁾. A meta-analysis based on data from 24 studies, including over 8400 participants from 13 countries, found the pooled prevalence rates of patients with smell and taste dysfunction were 41.0% and 38.2%, respectively⁽²⁹⁾. Another meta-analysis involving 18 studies showed that the prevalence of alteration of the sense of smell or taste was 47%⁽³⁰⁾. Importantly, recent studies have focused primarily on quantitative changes in smell and taste, while qualitative changes of smell and taste were not addressed^(29,31–33); however, we included five types of smell disorder (anosmia, hyposmia, parosmia, phantosmia and olfactory fluctuation), and four types of taste disorder (ageusia, hypogeusia, parageusia, phantogeusia) in our study. The prevalence of anosmia in our study was 23.3%, that of hyposmia was 42.5%, ageusia was 19.0%, and hypogeusia was 40.1%. Studies have also found that the prevalence of smell and taste disorder decreased during the period of Omicron variant dominance, but remained more than 30%, similar to our findings^(28,34).

Males are reported to be more prone to loss of smell and taste senses than females⁽³⁵⁾; however, our data demonstrate that females were more prone to complete loss of olfaction, similar to the findings of Lechien et al.^(6,8). In terms of taste loss, we did not detect significant differences between the sexes, similar to Al-Rawi et al.^(3,36). Further, Al-Rawi et al. found more significant smell and taste loss among individuals in their late 30s⁽³⁾, consistent with our finding that patients aged 30–39 years are more prone to anosmia and ageusia. Previous research showed that smokers are more vulnerable to anosmia and ageusia⁽³⁵⁾; however, we detected no significant differences between smokers and non-smokers in terms of anosmia and ageusia in our study. Interestingly, we found that smoking had adverse effects on smell disorders in general.

We also found that some COVID-19 related symptoms, such as lack of appetite, dyspnea, and fatigue, were associated with chemosensory disorder rates. Associations of these factors with chemosensory disorders have been reported in previous research^(7,8); however, whether they are risk factors for chemosensory disorders requires further study.

In the current study, we report the prevalence, quality, and quantity of chemosensory changes in patients infected with the Omicron variant in China. Patients often confuse chemesthesis with smell and taste when self-reporting, thus our survey included an expanded section relating to chemesthesis, with the aim of better distinguishing the influences of COVID-19 infection on smell, taste and chemesthesis. We also made detailed distinctions among the quality and quantity of changes in smell and taste, and found that these changes differed in the COVID-19 infected population, which may provide reference data for the follow-up research on the mechanism underlying COVID-19 influence on smell and taste. Moreover, we expanded the Chinese version of the GCCR core questionnaire, to provide reference data for future domestic research.

Our study also had several limitations. First, the participants were mostly from the southern areas of China. Second, the collection of the data for our study was based on self-report, which may lead to confirmation bias of chemosensory disorders. Additional objective assessment of chemosensory disorders is needed in future

studies. Third, our study was cross-sectional, and longitudinal studies are needed to determine the direction of associations among variables in our study. In conclusion, the current study found that the prevalence rates of smell, taste, and chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron variant dominance were 69.2%, 67.7%, and 31.4%, respectively. Patients experienced a general decline in the function of smell, taste, and chemesthesis. Sex, age, smoking, and COVID-19-related symptoms, such as lack of appetite, dyspnea, and fatigue, may be associated with chemosensory disorders during COVID-19. The present study contributes to existing knowledge of chemosensory disorders in COVID-19 by providing Chinese data collected during Omicron variant dominance.

ACKNOWLEDGEMENTS

We thank all the participants who participated in our study.

AUTHORSHIP CONTRIBUTION

Conceptualization, Laiquan Zou; formal analysis, Ying Chen, Yuying Chen, and Laiquan Zou; investigation, Ying Chen, Yuying Chen, Xiang Liu, Chao Yan, and Laiquan Zou; writing—original draft, Ying Chen, Yuying Chen, and Laiquan Zou; writing—review & editing, Xiang Liu, Chao Yan, and Laiquan Zou. All authors have read and agreed to the published version of the manuscript.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

FUNDING

None.

REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727–33.
2. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–20.
3. Al-Rawi NH, Sammouda AR, AlRahin EA, et al. Prevalence of Anosmia or Ageusia in Patients With COVID-19 Among United Arab Emirates Population. *Int Dent J*. 2022;72(2):249–56.
4. Lee S-H, Yeoh ZX, Sachlin IS, et al. Self-reported symptom study of COVID-19 chemosensory dysfunction in Malaysia. *Sci Rep*. 2022;12(1):2111.
5. Parma V, Ohla K, Veldhuizen MG, et al. More Than Smell—COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis. *Chem Senses*. 2020;45(7):609–22.
6. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol*. 2020;277(8):2251–61.
7. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med*. 2020;26(7):1037–40.
8. Tham AC, Thein T-L, Lee CS, et al. Olfactory taste disorder as a presenting symptom of COVID-19: a large single-center Singapore study. *Eur Arch Otorhinolaryngol*. 2021;278(6):1853–62.

- 302 9. Song J, Deng Y, Wang H, et al. Self-reported Taste and Smell Disorders in
303 Patients with COVID-19: Distinct Features in China. 2021;
- 304 10. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized
305 Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.*
306 2020;77(6):683.
- 307 11. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and
308 risk of hospital admission in individuals infected with SARS-CoV-2 during
309 periods of omicron and delta variant dominance: a prospective observational
310 study from the ZOE COVID Study. *The Lancet.* 2022;399(10335):1618–24.
- 311 12. Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2
312 variant of concern Omicron. *Cell Mol Immunol.* 2022;19(2):293–5.
- 313 13. Chee J, Chern B, Loh WS, Mullol J, Wang DY. Pathophysiology of SARS-
314 CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical
315 Impact. *Curr Allergy Asthma Rep.* 2023;23(2):121–31.
- 316 14. Rodriguez-Sevilla JJ, Güerri-Fernández R, Bertran Recasens B. Is There Less
317 Alteration of Smell Sensation in Patients With Omicron SARS-CoV-2 Variant
318 Infection? *Front Med.* 2022;9:852998.
- 319 15. von Bartheld CS, Wang L. Prevalence of Olfactory Dysfunction with the
320 Omicron Variant of SARS-CoV-2: A Systematic Review and Meta-Analysis.
321 *Cells.* 2023;12(3):430.
- 322 16. Li Q, Liu X, Li L, et al. Comparison of clinical characteristics between SARS-
323 CoV-2 Omicron variant and Delta variant infections in China. *Front Med.*
324 2022;9:944909.
- 325 17. Liang Y, Mao X, Kuang M, et al. Interleukin-6 affects the severity of olfactory
326 disorder: a cross-sectional survey of 148 patients who recovered from
327 Omicron infection using the Sniffin' Sticks test in Tianjin, China. *Int J Infect*
328 *Dis.* 2022;123:17–24.
- 329 18. Yang W, Yang S, Wang L, et al. Clinical characteristics of 310 SARS-CoV-2
330 Omicron variant patients and comparison with Delta and Beta variant patients
331 in China. *Viol Sin.* 2022;37(5):704–15.
- 332 19. Zhang H, Chen W, Ye X, et al. Clinical characteristics of patients infected with
333 novel coronavirus wild strain, Delta variant strain and Omicron variant strain
334 in Quanzhou: A real-world study. *Exp Ther Med.* 2022;25(1):62.
- 335 20. Shen J, Wu L, Wang P, et al. Clinical characteristics and short-term recovery
336 of hyposmia in hospitalized non-severe COVID-19 patients with Omicron
337 variant in Shanghai, China. *Front Med.* 2022;9:1038938.
- 338 21. Green BG. Chemesthesis and the Chemical Senses as Components of a
339 “Chemofensor Complex.” *Chem Senses.* 2012;37(3):201–6.
- 340 22. Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ,
341 Sedaghat AR. Olfactory Dysfunction and Sinonasal Symptomatology in
342 COVID-19: Prevalence, Severity, Timing, and Associated Characteristics.
343 *Otolaryngol Neck Surg.* 2020;163(1):114–20.
- 344 23. Iannilli E, Leopold DA, Hornung DE, Hummel T. Advances in Understanding
345 Parosmia: An fMRI Study. *ORL.* 2019;81(4):185–92.
- 346 24. Epstein JB, Smutzer G, Doty RL. Understanding the impact of taste changes in
347 oncology care. *Support Care Cancer.* 2016;24(4):1917–31.
- 348 25. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: A flexible statistical
349 power analysis program for the social, behavioral, and biomedical sciences.
350 *Behav Res Methods.* 2007;39(2):175–91.
- 351 26. Cecchetto C, Di Pizio A, Genovese F, et al. Assessing the extent and timing of

- chemosensory impairments during COVID-19 pandemic. *Sci Rep.* 2021;11(1):17504.
27. Albayay J, Fontana L, Parma V, Zampini M. Chemosensory Dysfunction in Long-Term COVID-19 Assessed by Self-Reported and Direct Psychophysical Methods. *Life.* 2022;12(10):1487.
28. Song J, Jing Q, Zhu E, et al. Alterations in smell or taste in individuals infected with SARS-CoV-2 during periods of Omicron variant dominance. *Int J Infect Dis.* 2023;128:278–84.
29. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. *Mayo Clin Proc.* 2020;95(8):1621–31.
30. Borsetto D, Hopkins C, Philips V, et al. Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. *Rhinology.* 2020;58(5):430–6.
31. Luers JC, Rokohl AC, Loreck N, et al. Olfactory and Gustatory Dysfunction in Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2020;71(16):2262–4.
32. Mercante G, Ferreli F, De Virgilio A, et al. Prevalence of Taste and Smell Dysfunction in Coronavirus Disease 2019. *JAMA Otolaryngol-- Head Neck Surg.* 2020;146(8):1–6.
33. Pellegrino R, Mainland JD, Kelly CE, Parker JK, Hummel T. Prevalence and correlates of parosmia and phantosmia among smell disorders. *Chem Senses.* 2021;46:bjab046.
34. Boscolo Rizzo P, Tirelli G, Meloni P, et al. Coronavirus disease 2019 (COVID-19)-related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) Omicron variant. *Int Forum Allergy Rhinol.* 2022;12(10):1273–81.
35. Al-Ani RM, Acharya D. Prevalence of Anosmia and Ageusia in Patients with COVID-19 at a Primary Health Center, Doha, Qatar. *Indian J Otolaryngol Head Neck Surg.* 2022;74(S2):2703–9.
36. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol.* 2020;10(8):944–50.

CORRESPONDING AUTHOR

Laiquan Zou

Chemical Senses and Mental Health Lab, Department of Psychology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China

Tel.: +86-20-62789234

zoulq@smu.edu.cn;


FIGURES

393

394

395

Figure 1 The results of self-rating of smell, taste, and chemesthesis function



396

397

398

399

 $p < 0.001$.

400 TABLES

401 **Table 1 The prevalence of smell, taste, and chemesthesis disorders among**
 402 **patients with COVID-19**

Variable	n	Total prevalence (N = 1245)	Prevalence in people with smell/taste/chemesthesis disorder
Smell disorder*	861	69.2%	\
Anosmia	290	23.3%	33.7%
Hyposmia	529	42.5%	61.4%
Parosmia	60	4.8%	7.0%
Phantosmia	98	7.9%	11.4%
Smell fluctuation	438	35.2%	50.9%
Taste disorder*	843	67.7%	\
Ageusia	236	19.0%	28.0%
Hypogeusia	499	40.1%	59.2%
Parageusia	282	22.7%	33.5%
Phantogeusia	333	26.7%	39.5%
Chemesthesis disorder	391	31.4%	\
Complete loss	35	2.8%	9.0%
Partial loss	356	28.6%	91.0%

403 *Multiple responses

404

Table 2 Association between smell disorder and demographic/COVID-19-related characteristics among patients

Variable	Smell disorder (%)		Total (%)	p value
	Yes (n = 861)	No (n = 384)	N = 1245	
Sex				
Male	170 (19.7)	92 (24.0)	262 (21.0)	0.092
Female	691 (80.3)	292 (76.0)	983 (79.0)	
Age, years				
18–29	702 (81.5)	327 (85.2)	1029 (82.7)	0.204
30–39	116 (13.5)	38 (9.9)	154 (12.4)	
40–49	30 (3.5)	16 (4.2)	46 (3.7)	
≥ 50	13 (1.5)	3 (0.8)	16 (1.3)	
Smoking				
Current	32 (3.7)	5 (1.3)	37 (3.0)	0.012
Former	38 (4.4)	9 (2.3)	47 (3.8)	
Never	791 (91.9)	370 (96.4)	1161 (93.3)	
Alcohol				
Yes	441 (51.2)	184 (47.9)	625 (50.2)	0.282
No	420 (48.8)	200 (52.1)	620 (49.8)	
Chronic rhinitis				
Yes	137 (15.9)	48 (12.5)	185 (14.9)	0.118
No	724 (84.1)	336 (87.5)	1060 (85.1)	
Allergic rhinitis				
Yes	208 (24.2)	91 (23.7)	299 (24.0)	0.861
No	653 (75.8)	293 (76.3)	946 (76.0)	
Any comorbidity or special condition [#]				
Yes	106 (12.3)	42 (10.9)	148 (11.9)	0.489
No	755 (87.7)	342 (89.1)	1097 (88.1)	
Method of diagnosis				
PCR test	134 (15.6)	67 (17.4)	201 (16.1)	0.706
Antigen test	459 (53.3)	200 (52.1)	659 (52.9)	
Symptoms	268 (31.1)	117 (30.5)	385 (30.9)	
Rehabilitation status				
Complete	283 (32.9)	167 (43.5)	450 (36.1)	< 0.001
Partial	578 (67.1)	217 (56.5)	795 (63.9)	
Symptoms [*]				
Fever	818 (95.0)	358 (93.2)	1176 (94.5)	0.206
Lack of appetite	547 (63.5)	168 (43.8)	715 (57.4)	< 0.001
Dry and sore throat	692 (80.4)	284 (74.0)	976 (78.4)	0.011
Myalgia	604 (70.2)	240 (62.5)	844 (67.8)	0.008
Headache	598 (69.5)	256 (66.7)	854 (68.6)	0.328
Diarrhea	191 (22.2)	71 (18.5)	262 (21.0)	0.140
Cough/expectorations	747 (86.8)	321 (83.6)	1068 (85.8)	0.140
Stuffy/running nose	704 (81.8)	281 (73.2)	985 (79.1)	0.001
Dyspnea	158 (18.4)	43 (11.2)	201 (16.1)	0.002
Fatigue	602 (69.9)	232 (60.4)	834 (67.0)	0.001

COVID-19 vaccination

Yes (n = 1208)	828 (96.2)	380 (99.0)	1208 (97.0)	0.007
No (n = 37)	33 (3.8)	4 (1.0)	37 (3.0)	

407 #Comorbidity or special condition includes hypertension, diabetes, cardiovascular
408 disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic
409 kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial
410 asthma, mental illness, and in the third trimester of pregnancy or perinatal period.
411 *Multiple responses
412

Table 3 Association between taste disorder and demographic/COVID-19-related characteristics among patients

Variable	Taste disorder (%)		Total (%)	p value
	Yes (n = 843)	No (n = 402)	Yes (n = 1245)	
Sex				
Male	167 (19.8)	95 (23.6)	262 (21.0)	0.122
Female	676 (80.2)	307 (76.4)	983 (79.0)	
Age, years				
18–29	687 (81.5)	342 (85.1)	1029 (82.7)	0.430
30–39	113 (13.4)	41 (10.2)	154 (12.4)	
40–49	32 (3.8)	14 (3.5)	46 (3.7)	
≥ 50	11 (1.3)	5 (1.2)	16 (1.3)	
Smoking				
Current	27 (3.2)	10 (2.5)	37 (3.0)	0.194
Former	37 (4.4)	10 (2.5)	47 (3.8)	
Never	779 (92.4)	382 (95.0)	1161 (93.3)	
Alcohol				
Yes	430 (51.0)	195 (48.5)	625 (50.2)	0.409
No	413 (49.0)	207 (51.5)	620 (49.8)	
Chronic rhinitis				
Yes	129 (15.3)	56 (13.9)	185 (14.9)	0.524
No	714 (84.7)	346 (86.1)	1060 (85.1)	
Allergic rhinitis				
Yes	206 (24.4)	93 (23.1)	299 (24.0)	0.615
No	637 (75.6)	309 (76.9)	946 (76.0)	
Any comorbidity or special condition [#]				
Yes	109 (12.9)	39 (9.7)	148 (11.9)	0.100
No	734 (87.1)	363 (90.3)	1097 (88.1)	
Method of diagnosis				
PCR test	135 (16.0)	66 (16.4)	201 (16.1)	0.466
Antigen test	438 (52.0)	221 (55.0)	659 (52.9)	
Symptoms	270 (32.0)	115 (28.6)	385 (30.9)	
Rehabilitation status				
Complete	292 (34.6)	158 (39.3)	450 (36.1)	0.109
Partial	551 (65.4)	244 (60.7)	795 (63.9)	
Symptoms [*]				
Fever	800 (94.9)	376 (93.5)	1176 (94.5)	0.324
Lack of appetite	554 (65.7)	161 (40.0)	715 (57.4)	< 0.001
Dry and sore throat	677 (80.3)	299 (74.4)	976 (78.4)	0.017
Myalgia	591 (70.1)	253 (62.9)	844 (67.8)	0.011
Headache	599 (71.1)	255 (63.4)	854 (68.6)	0.007
Diarrhea	196 (23.3)	66 (16.4)	262 (21.0)	0.006
Cough/expectorations	739 (87.7)	329 (81.8)	1068 (85.8)	0.006
Stuffy/running nose	681 (80.8)	304 (75.6)	985 (79.1)	0.036
Dyspnea	158 (18.7)	43 (10.7)	201 (16.1)	< 0.001
Fatigue	598 (70.9)	236 (58.7)	834 (67.0)	< 0.001

COVID-19 vaccination

Yes	814 (96.6)	394 (98.0)	1208 (97.0)	0.159
No	29 (3.4)	8 (2.0)	37 (3.0)	

415 #Comorbidity or special conditions included hypertension, diabetes, cardiovascular
416 disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic
417 kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial
418 asthma, mental illness, and in the third trimester of pregnancy or perinatal period.

419 * Multiple responses.

420

Table 4 Association between chemesthesis disorder and patient demographic characteristics

Variable	Chemesthesis disorder (%)		Total (%)	p value
	Yes (n = 391)	No (n = 854)	Yes (n = 1245)	
Sex				
Male	70 (17.9)	192 (22.5)	262 (21.0)	0.066
Female	321 (82.1)	662 (77.5)	983 (79.0)	
Age, years				
18–29	310 (79.3)	719 (84.2)	1029 (82.7)	0.160
30–39	60 (15.3)	94 (11.0)	154 (12.4)	
40–49	15 (3.8)	31 (3.6)	46 (3.7)	
≥ 50	6 (1.5)	10 (1.2)	16 (1.3)	
Smoking				
Current	12 (3.1)	25 (2.9)	37 (3.0)	0.914
Former	16 (4.1)	31 (3.6)	47 (3.8)	
Never	363 (92.8)	798 (93.4)	1161 (93.3)	
Alcohol				
Yes	203 (51.9)	422 (49.4)	625 (50.2)	0.412
No	188 (48.1)	432 (50.6)	620 (49.8)	
Chronic rhinitis				
Yes	62 (15.9)	123 (14.4)	185 (14.9)	0.503
No	329 (84.1)	731 (85.6)	1060 (85.1)	
Allergic rhinitis				
Yes	86 (22.0)	213 (24.9)	299 (24.0)	0.259
No	305 (78.0)	641 (75.1)	946 (76.0)	
Any comorbidity or special condition [#]				
Yes	49 (12.5)	99 (11.6)	148 (11.9)	0.635
No	342 (87.5)	755 (88.4)	1097 (88.1)	
Method of diagnosis				
PCR test	60 (15.3)	141 (16.5)	201 (16.1)	0.693
Antigen test	204 (52.2)	455 (53.3)	659 (52.9)	
Symptoms	127 (32.5)	258 (30.2)	385 (30.9)	
Rehabilitation status				
Complete	126 (32.2)	324 (37.9)	450 (36.1)	0.051
Partial	265 (67.8)	530 (62.1)	795 (63.9)	
Symptoms [*]				
Fever	369 (94.4)	807 (94.5)	1176 (94.5)	0.930
Lack of appetite	261 (66.8)	454 (53.2)	715 (57.4)	< 0.001
Dry and sore throat	312 (79.8)	664 (77.8)	976 (78.4)	0.416
Myalgia	270 (69.1)	574 (67.2)	844 (67.8)	0.519
Headache	266 (68.0)	588 (68.9)	854 (68.6)	0.772
Diarrhea	84 (21.5)	178 (20.8)	262 (21.0)	0.797
Cough/expectorations	341 (87.2)	727 (85.1)	1068 (85.8)	0.329
Stuffy/running nose	309 (79.0)	676 (79.2)	985 (79.1)	0.959
Dyspnea	87 (22.3)	114 (13.3)	201 (16.1)	< 0.001
Fatigue	284 (72.6)	550 (64.4)	834 (67.0)	0.004

COVID-19 vaccination

Yes	374 (95.7)	834 (97.7)	1208 (97.0)	0.053
No	17 (4.3)	20 (2.3)	37 (3.0)	

423 #Comorbidity or special conditions included hypertension, diabetes, cardiovascular
424 disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic
425 kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial
426 asthma, mental illness, and in the third trimester of pregnancy or perinatal period.
427 * Multiple response.
428